BeNeLuxBelgiumNetherlandsLuxembourg

Wyeth closes 165 million Euros deal

21.11.2006

Brussels – Just before the commencement of clinical trials, Ablynx, a Belgian biotech company which is developing a new class of drugs based on DNA, has closed a deal worth up a165 million with the US vaccines specialist Wyeth. The agreement allows Wyeth to develop a new generation of anti-TNF treatments for diseases such as rheumatoid arthritis using ultra-small nanobodies. Ablynx has granted exclusive worldwide rights for the use of the technology to target tumor necrosis factor alpha (TNFa), a protein implicated in inflammation, which is inhibited by existing injectable drugs such Wyeth’s Enbrel. Backed by this important pharma deal, Ablynx hopes to go public next year.

BeNeLuxBelgiumNetherlandsLuxembourg

06.10.2011

Hamburg/Brussels - Evotec AG and UCB Pharma seem to be satisfied with their relationship. The Belgian pharmaceutical company entered into a second multi-year, multi-target integrated drug discovery collaboration with Evotec in...

BeNeLuxBelgiumNetherlandsLuxembourg

05.10.2011

Luxembourg - For its tiny size, Luxembourg attracts a disproportionally huge amount of venture capital. Creabilis SA has raised €15m in a Series B funding round led by Abbott Biotech Ventures. "In Abbott, we have added another...

BeNeLuxBelgiumNetherlandsLuxembourg

01.10.2011

Munich/Amsterdam – Researchers from the LMU Munich and the Aca­demic Medical Center Amsterdam have found a way to predict disease outcome in patients with life-threatening bacterial meningitis. In a nation­wide genetic...

BeNeLuxBelgiumNetherlandsLuxembourg

01.10.2011

Utrecht – Consuming fish or fish oil capsules may be a bad idea for cancer patients, according to Dutch researchers. In mid-September, a team headed by Emile Voest from the University Medical Centre Utrecht reported such products...

BeNeLuxBelgiumNetherlandsLuxembourg

01.10.2011

Rotterdam – Finnish oil refining company Neste Oil corporation has kick-started production in Europe’s largest renewable diesel refinery in Rotterdam. The plant has a capacity of 800,000 tonnes a year, and this will be ramped up...

BeNeLuxBelgiumNetherlandsLuxembourg

01.10.2011

Brussels – A European gateway to life science capacities has been launched (www.toolsofscience.eu) that is aimed at providing a novel resource for identifying the best facilities and service companies from among 13 bioregions...

BeNeLuxBelgiumNetherlandsLuxembourg

01.10.2011

Stockholm/Leiden/Barcelona – A complicated ménage a trois has come to an end: Swedish Orphan Biovitrum AB, Pharming Group N.V. and Esteve S.A. announced at the beginning of September that they were terminating a 2004 deal...

BeNeLuxBelgiumNetherlandsLuxembourg

14.09.2011

Bunnik – AM-Pharma B.V. has raised €29.2m. The Dutch company plans to spend the money on delivering a human recombinant form of Alkaline Phosphatase (AP) as a treatment for Acute Kidney Injury (AKI) from preclinical stages to the...

BeNeLuxBelgiumNetherlandsLuxembourg

13.09.2011

Utrecht – Researchers at University Medical Center Utrecht have dealt a blow to the advocates of allegedly healthy fish oil. The substance which is again and again named as a helpful substance for cancer patients, seems instead...

Displaying results 21 to 30 out of 304

< Previous 21-30 Next >

© 2007-2015 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-benelux/browse/2/article/wyeth-closes-165-million-euros-deal.html

Whitepaper

Video

All videos

Product of the week

Products

Events

All Events

Stock list

All quotes

TOP

  • BIOTIE THERAPEUTICS (FI)0.23 EUR43.75%
  • DIAXONHIT (F)0.79 EUR14.49%
  • ACTIVE BIOTECH (S)12.35 SEK10.27%

FLOP

  • ZELTIA (E)3.69 EUR-8.44%
  • SWEDISH ORPHAN BIOVITRUM (S)13.05 USD-6.12%
  • ALMIRALL (E)17.75 EUR-5.84%

TOP

  • DBV TECHNOLOGIES (F)79.24 EUR50.2%
  • BIOTIE THERAPEUTICS (FI)0.23 EUR43.8%
  • DIAXONHIT (F)0.79 EUR43.6%

FLOP

  • BIOTEST (D)25.52 EUR-63.3%
  • BIOTECH PHARMACON (N)9.45 NOK-46.0%
  • EVOCUTIS (UK)0.17 GBP-22.7%

TOP

  • ADOCIA (F)86.78 EUR572.2%
  • DBV TECHNOLOGIES (F)79.24 EUR319.3%
  • FORMYCON (D)28.40 EUR311.6%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-88.9%
  • NEUROVIVE PHARMACEUTICAL AB (S)22.10 SEK-72.4%
  • NEOVACS (F)1.02 EUR-69.2%

No liability assumed, Date: 03.08.2015

Current issue

All issues